Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues.

@article{Adam2016MetforminEO,
  title={Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues.},
  author={Jonathan Adam and Stefan Brandmaier and J{\"o}rn Leonhardt and Markus F Scheerer and Robert P. Mohney and Tao Xu and Jie Bi and Markus Rotter and Martina Troll and Shen Chi and Margit Heier and Christian Herder and Wolfgang Rathmann and G. Giani and Jerzy Adamski and Thomas Illig and Konstantin Strauch and Yixue Li and Christian Gieger and Annette Peters and Karsten Suhre and Donna P. Ankerst and Thomas Meitinger and Martin Hrabě de Angelis and Michael Roden and Susanne Neschen and Gabi Kastenm{\"u}ller and Rui Wang-Sattler},
  journal={Diabetes},
  year={2016},
  volume={65 12},
  pages={
          3776-3785
        }
}
Metformin is the first-line oral medication to increase insulin sensitivity in patients with type 2 diabetes (T2D). Our aim was to investigate the pleiotropic effect of metformin using a nontargeted metabolomics approach. We analyzed 353 metabolites in fasting serum samples of the population-based human KORA (Cooperative Health Research in the Region of Augsburg) follow-up survey 4 cohort. To compare T2D patients treated with metformin (mt-T2D, n = 74) and those without antidiabetes medication… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS